Semaglutide 2.4 mg,
does it really help with Reduced composite risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with overweight or obesity, cardiovascular disease, and no diabetes?
research showsSemaglutide 2.4 mg is rated A because it reduces three-point major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity but no diabetes. SELECT was an event-driven, double-blind, placebo-controlled trial of 17,604 participants followed for a mean of 39.8 months; first cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% versus 8.0%, with HR 0.80 (95% CI 0.72 to 0.90). This is direct hard-endpoint evidence from randomized addition of semaglutide 2.4 mg to standard cardiovascular care. Among individual components, however, only nonfatal myocardial infarction was clearly significant, confidence intervals for cardiovascular death and nonfatal stroke included no effect, and Novo Nordisk funded the trial. This is a SELECT cardiovascular secondary-prevention verdict, not a weight-loss verdict.
ads claimMarketing may simplify the finding to losing weight prevents heart attacks and strokes. SELECT directly established that adding semaglutide 2.4 mg to standard care reduced composite MACE in adults with established cardiovascular disease, overweight or obesity, and no diabetes. The trial alone does not establish that weight loss itself, primary prevention, or every other GLP-1 drug has the same effect.
Useful facts when choosing a product
- Wegovy is a once-weekly subcutaneous semaglutide injection that is started at a low dose and escalated stepwise to 2.4 mg according to gastrointestinal tolerability. The prescribed titration schedule and product label take priority.
- SELECT enrolled adults aged at least 45 years with BMI at least 27 kg/m², prior myocardial infarction, stroke, or peripheral artery disease, and no history of diabetes. The same effect size cannot be assumed outside these conditions.
- Nausea, vomiting, diarrhea, constipation, and abdominal pain are common, and adverse events led to permanent discontinuation in 16.6% with semaglutide versus 8.2% with placebo in SELECT.
- Gallbladder disease and acute pancreatitis require attention, and severe gastrointestinal symptoms or dehydration can worsen kidney function. Product contraindications should be checked in people with a personal or family history of medullary thyroid carcinoma or MEN2.
What the research actually shows
Lincoff and the SELECT Trial Investigators enrolled 17,604 adults aged at least 45 years with BMI at least 27 kg/m², established cardiovascular disease, and no history of diabetes. Once-weekly subcutaneous semaglutide 2.4 mg or placebo was added to standard care, and the primary three-point MACE hazard ratio was 0.80. Nonfatal myocardial infarction was clearly reduced, HR 0.72 (95% CI 0.61 to 0.85), whereas cardiovascular death and nonfatal stroke had hazard ratios of 0.85 and 0.93 with confidence intervals crossing 1. A prespecified HbA1c analysis found a consistent MACE direction across baseline glycemic categories. The 2025 SELECT safety analysis found fewer serious adverse events overall but more adverse-event discontinuations, 16.6% versus 8.2%, driven mainly by gastrointestinal disorders. SELECT and its follow-up analyses were supported by Novo Nordisk and are not described as funding-independent evidence.
Why this is classified as A (90)
In the 17,604-participant double-blind, placebo-controlled SELECT trial, three-point MACE fell from 8.0% to 6.5%, HR 0.80 (95% CI 0.72 to 0.90). A large event-driven trial isolated the ingredient as an addition to standard care and reduced direct cardiovascular hard outcomes, supporting A. Manufacturer funding, nonsignificant individual cardiovascular-death and stroke components, and the 1.5-percentage-point absolute reduction set the score at 90.
Counterpoint. For eligible high-risk patients this is a secondary-prevention option beyond weight loss, but it does not replace antiplatelet therapy, lipid lowering, blood-pressure treatment, or smoking cessation. Cost, ability to sustain injections, gastrointestinal adverse effects, and personal absolute risk should be considered together.
Rejudgment record. New verdict — Applied rule ⑤ to the direct hard-endpoint evidence from the 17,604-participant, double-blind, placebo-controlled, event-driven SELECT trial, in which adding semaglutide 2.4 mg to standard care reduced three-point MACE with HR 0.80, while deducting for manufacturer funding and limited precision of individual components
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction in three-point MACE of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke | A | The 17,604-participant direct hard-endpoint trial found 6.5% versus 8.0%, HR 0.80. |
| Reduction in nonfatal myocardial infarction | B | The individual component had HR 0.72 (95% CI 0.61 to 0.85), but it was subordinate to the primary composite endpoint. |
| Reduction in cardiovascular death | C | HR was 0.85 (95% CI 0.71 to 1.01), favorable in direction but not excluding no effect or meeting the prespecified threshold. |
| Reduction in nonfatal stroke | C | HR was 0.93 (95% CI 0.74 to 1.15), so an individual reduction was not established. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Lincoff AM et al.; SELECT Trial Investigators. 2023 | Multicenter double-blind randomized placebo-controlled event-driven superiority trial | 8,801 | Funded by Novo Nordisk | First three-point MACE of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke | Three-point MACE was 6.5% versus 8.0%, HR 0.80 (95% CI 0.72 to 0.90; P<0.001), over mean follow-up of 39.8 months. | Pivotal large direct hard-endpoint randomized trial |
| Lingvay I et al.; SELECT Trial Investigators. 2024 | Prespecified SELECT subgroup analysis by HbA1c | 17,604 | Funded by Novo Nordisk | Three-point MACE and cardiovascular outcomes by baseline and change in HbA1c | The direction of MACE reduction with semaglutide was consistent across baseline HbA1c categories. | Supportive consistency analysis |
| Kushner RF et al. 2025 | Prespecified safety analysis of the SELECT randomized trial | 17,604 | Funded by Novo Nordisk with company employees as coauthors | Serious adverse events, discontinuation events, and adverse events of special interest | Serious adverse events were 33.4% versus 36.4%, but adverse-event discontinuation was 16.6% versus 8.2% and gallbladder disorders were 2.8% versus 2.3%. | Large safety evidence kept separate from efficacy |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Semaglutide 2.4 mg x prevention of major cardiovascular events in adults with overweight or obesity and no diabetes — Evidence Grade A·90. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/semaglutide-2-4mg-cvd-overweight-obesity-mace-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.